Metabolic
Tirzepatide
GIP/GLP-1 dual agonist · LY3298176
Dual GIP and GLP-1 receptor agonist with the deepest weight-change effect of any approved incretin.
5 mg10 mg15 mg20 mg30 mg +5
Retatrutide
Also known as: GGG triple agonist · LY3437943
Metabolic & GLP-1 In stock Box of 10 vials 1 reference
Triple GIP / GLP-1 / glucagon receptor agonist — the next generation of incretin research.
Available sizes
| SKU | Per vial | Pack | |
|---|---|---|---|
| RT5 | 5 mg | 10 vials / box | |
| RT10 | 10 mg | 10 vials / box | |
| RT15 | 15 mg | 10 vials / box | |
| RT20 | 20 mg | 10 vials / box | |
| RT30 | 30 mg | 10 vials / box | |
| RT40 | 40 mg | 10 vials / box | |
| RT50 | 50 mg | 10 vials / box | |
| RT60 | 60 mg | 10 vials / box | |
| RT100 | 100 mg | 10 vials / box |
Order Retatrutide
Pricing is quoted directly and is competitive at every tier — message us with the SKUs you want and quantities for a quote.
Replies within 36 hours. Cryptocurrency (preferred) or card / money-app with a processing fee. COA for this batch available on request.
Retatrutide is a single-peptide agonist at three receptors: GIP, GLP-1 and glucagon. Adding glucagon-receptor activity to the incretin mechanism is hypothesised to increase energy expenditure alongside reduced intake.
In a 48-week phase 2 trial (n = 338), retatrutide 12 mg produced a mean weight change of −24.2% versus −2.1% with placebo, with a dose-dependent response across the 1–12 mg range 1. Phase 3 (TRIUMPH) trials are ongoing, making retatrutide one of the most closely watched compounds in metabolic research.
At a glance
- Agonist at GIP, GLP-1 and glucagon receptors
- Phase 2: −24.2% mean weight change at 48 weeks (12 mg)
- Supplied 5 mg through 100 mg per vial
Research use only. All products are sold strictly for laboratory research and development purposes. They are not intended for human or veterinary use, diagnosis, treatment, cure or prevention of any disease. Not for human consumption. Summaries above describe published findings in laboratory and clinical research models and do not constitute claims about this product.
- Form
- Lyophilized powder
- Purity
- HPLC-verified — Certificate of Analysis available on request
- Pack size
- Box of 10 vials
- Storage
- Lyophilized: −20 °C, protected from light (2–8 °C short-term). Reconstituted: 2–8 °C.
- Formula
- C221H342N46O68
- Mol. weight
- 4731.3 g/mol
- CAS No.
- 2381089-83-2
Sequence, formula and CAS data are provided for identification. Batch-specific purity, mass-spec and HPLC data are on the Certificate of Analysis — ask for it with your order.
- Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526.
Citations retrieved from PubMed (NCBI). Links open the publisher record via DOI and the PubMed abstract.
Related
Often ordered together
Metabolic Blend
Retatrutide + Cagrilintide
Triple agonist + amylin blend
Triple-agonist and amylin analogue co-formulated 1:1.
10 mg (5 + 5)
Metabolic Blend
Retatrutide + Tirzepatide
Triple + dual agonist blend
High-mass co-formulation of retatrutide and tirzepatide for combination-agonist studies.
60 mg (20 + 40)